GYN Solutions & Aesthetics Explains Its HRT Process and Reviews New National Menopause Guidance
ST. PETERSBURG, FL - November 16, 2026 - PRESSADVANTAGE - GYN Solutions & Aesthetics is outlining its HRT process for
Press Release Disclaimer: This is a press release distributed through the XPR Media network. It has not been independently verified by our newsroom.

![]()
ST. PETERSBURG, FL – November 16, 2026 – PRESSADVANTAGE –
GYN Solutions & Aesthetics is outlining its HRT process for patients in St. Petersburg while reviewing new menopause guidance from the American College of Obstetricians & Gynecologists (ACOG). Published October 15, 2026, the guideline replaces a 2014 practice bulletin and addresses hot flashes, night sweats, sleep problems, and mood symptoms.
The practice’s article on hormone therapy and sleep explains why some patients wake more often during menopause.

ACOG reports that 50% to 92% of women in menopause experience hot flashes or night sweats. For patients who can safely use hormones, ACOG strongly recommends systemic hormone therapy for these symptoms and related sleep disruption. Systemic hormone therapy works throughout the body.
When patients choose this treatment, ACOG recommends starting before age 60 or within 10 years of natural menopause.
After age 60 or more than 10 years after menopause begins, the underlying risk of coronary heart disease is higher. The risks of blood clots and stroke are also higher at that point, and starting hormone therapy may raise those two risks further.
Even when a patient falls within the recommended starting window, ACOG advises weighing the risks associated with both age and time since menopause against the potential benefits of starting hormone therapy.
Menopause symptoms can develop gradually, making them easy to attribute to stress or aging. Hot flashes and night sweats may occur as estrogen levels fluctuate during perimenopause. Patients may also report mood changes or vaginal dryness. Some experience fatigue that persists despite rest. These concerns can have different causes and help guide the discussion at the first visit.
At the practice’s St. Petersburg office, the HRT process begins with a review of symptoms and medical history. The evaluation may include blood tests when the clinician needs more information. The clinician asks when symptoms started and how they affect daily life, then looks for medical reasons that could make hormone therapy unsuitable.
When hormone therapy is appropriate, the clinician develops a treatment plan with the patient. The practice commonly considers estrogen and progesterone therapy. The plan reflects which symptoms the patient wants to address and how they prefer to receive hormone therapy.
For patients with a uterus, ACOG generally recommends adding a progestogen to systemic estrogen. A progestogen acts like progesterone and helps protect the uterine lining, reducing the risk of endometrial cancer associated with taking estrogen alone. The guideline also identifies a combination of conjugated estrogen and bazedoxifene as an option for some patients.
Estrogen alone is an option for eligible patients who do not need that protection, such as those who have had their uterus removed.
One treatment option in the practice’s HRT process is the EVEXIAS system, which uses compounded bioidentical hormone pellets placed just under the skin. The pellets are designed to release hormones over several months. EVEXIAS identifies estradiol and testosterone as its pellet formulations and lists progesterone as a separate form of hormone therapy.
In separate guidance on compounded hormone therapy, ACOG recommends FDA-approved menopausal hormone formulations over compounded products when a suitable alternative is available.
Follow-up continues while patients use hormone therapy. ACOG advises reassessing symptom relief and side effects at three months, then annually unless an earlier review is needed. The patient and clinician review the patient’s symptoms and weigh the benefits and risks of staying on hormone therapy before deciding when and how to stop.
The guideline also discusses nonhormonal medications for patients who cannot or prefer not to use hormone therapy, along with options that do not involve medication. For example, ACOG suggests cognitive behavioral therapy for hot flashes, night sweats, and menopause-related sleep or mood symptoms.
ACOG is developing separate guidance, expected in 2027, on the genitourinary syndrome of menopause, which includes vaginal dryness and urinary symptoms.
GYN Solutions & Aesthetics is led by Dr. Leslie Bender-Ralph, a board-certified OB/GYN with more than 14 years of clinical experience. The practice offers hormone therapy, other gynecologic care, and aesthetic treatments in St. Petersburg.
###
For more information about GYN Solutions & Aesthetics, contact the company here:
GYN Solutions & Aesthetics – St. Petersburg, FL
Dr. Bender-Ralph, Dr. Leslie Bender-Ralph
tel:7275130231
info@gsatampa.com
1236 Dr M.L.K. Jr St N, St. Petersburg, FL 33705, United States